The lipoprotein abnormalities were more pronounced in patients with high HbA1c values. In addiBackground. Diabetic nephropathy (DN ) is a common cause of chronic renal failure (CRF ). Patients with tion, lower GFR and increased proteinuria were associated with higher concentrations of triglycerides DN have abnormal lipoprotein metabolism that can be influenced by both the impairment of renal function and apoC peptides in VLDL, IDL, and LDL in DN patients. and the metabolic control of diabetes. The aim of the study was to explore the specific compositional lipopro-Conclusions. The results indicate that patients with DN share the characteristic features of dyslipidaemia tein abnormalities in patients with insulin-dependent DN in comparison with diabetic patients without of CRF with accumulation of intact or partially delipidized apoB-containing lipoproteins enriched in nephropathy and non-diabetic CRF patients. Methods. The lipid and apolipoprotein (apo) composi-apoC-peptides and apoE, which are present not only in VLDL and IDL but also in LDL density range. The tion of major lipoprotein density classes was determined in 20 patients with insulin-dependent diabetes alterations are more marked in DN than in nondiabetic CRF patients reflecting the additional impact mellitus and nephropathy and compared with that in seven diabetic patients without nephropathy, 20 of metabolic control. Increased levels of these lipoproteins may represent risk factors for the accelerated patients with non-diabetic CRF, and nine healthy control subjects. Lipoproteins isolated by preparative development of atherosclerotic vascular disease in these patients. ultracentrifugation were very-low-density lipoproteins ( VLDL), intermediate-density lipoproteins (IDL), Key words: apolipoproteins; lipids; lipoproteins; insulow-density lipoproteins (LDL), and high-density lipolin-dependent diabetes mellitus; renal failure proteins (HDL). Results. Patients with DN had a plasma lipid and apolipoprotein profile characteristic of renal dyslipoproteinaemia with increased concentrations of tri-Introduction glycerides and cholesterol, reduced levels of apoA-I and apoA-II and increased levels of apoB, apoC-II, Patients with diabetic nephropathy (DN ) constitute a apoC-III and apoE. These changes were more pro-major proportion of patients with chronic renal failure nounced in diabetic than in non-diabetic patients with (CRF ) treated with dialysis and transplantation [1, 2]. comparable degrees of renal failure.
function as measured by the glomerular filtration rate (GFR) diabetic patients with progressive nephropathy and [8] with a mean value of 19.5±12.2 ml/1.73 m2 body surface moderately to severely impaired renal function have area. The mean concentration of glycated haemoglobin altered lipid and apolipoprotein profiles that were in (HbA1c) was 9.5±1.3%, significantly higher than that in the many respects similar to those of non-diabetic patients diabetic controls without nephropathy (P<0.05). Eighteen with comparable degree of renal insufficiency, and that patients were treated for hypertension, mostly with cardiothe diabetic state could further accentuate these selective beta-blocking drugs and furosemide. Macrovascular changes [7] . complications in coronary, cerebral and major peripheral
The purpose of the present study was to determine vessels were present in 12 patients. The patients had increased lipoprotein composition in insulin-dependent diabetic 24 h urinary protein excretion with a mean value of 2.4±1.8 g at the time of study (n=18). None of the patients were patients with moderate to severe renal failure and to severely nephrotic and the mean serum albumin concentracompare it with that in non-diabetic patients with tion was 42.4±8.4 g/l (n=13) and the mean serum protein CRF. The specific aim was to determine the changes concentration was 66.5±11.0 g/l (n=19). There was no in lipid and apolipoprotein concentrations and comevidence of other primary renal disease. Renal biopsy was position of major lipoprotein density classes in patients performed for reasons not related to the present study in 12 with DN.
patients and only revealed histopathological changes of DN. The remaining eight patients had a duration of diabetes of 9-19 years until manifest proteinuria and they all had Subjects and methods diabetic retinopathy.
Patients with DN were treated with insulin regimens of multiple injections of short-acting insulin combined with Study subjects medium-or long-acting insulin. The patients monitored their blood glucose homeostasis by self control. In addition to the Patients and control subjects were recruited from a larger antihypertensive and diuretic drugs, the treatment with phosgroup of subjects described previously [7] . All patients were phate binders, sodium bicarbonate and vitamins was used as treated at the Department of Nephrology and Medicine, appropriate. All diabetic patients received dietary counselling University of Gö teborg.
for diabetes, but no specific counselling on lipid-lowering diets. A few patients with severely restricted renal function
Diabetic patients
were prescribed a moderate dietary protein restriction. None of the patients were treated with steroids or drugs known to Twenty-seven patients (17 men, 10 women) with insulin-influence lipid metabolism. dependent diabetes mellitus (type I ) were studied. The clinical characteristics of patients are shown in Table 1 .
Seven of the patients (5 men, 2 women) had no clinical Non-diabetic patients with renal insufficiency signs of nephropathy; they had normal serum creatinine and urinary albumin excretion did not exceed 6 mg/l in any Twenty patients with renal insufficiency from primary renal disease with similar range of age and GFR as the diabetic patient. Their mean age was 45.5 years (range 27-63 years) and they had a mean duration of diabetes of 26.2±11.7 patients were studied as a reference patient group. These patients have been described previously [9] . The clinical years. The selection of diabetic patients without nephropathy was based on a similar duration of disease as patients with characteristics are summarized in Table 1. There were 11 men and 9 women with a mean age of 45.9 years (range renal disease. The patients were in good physical condition without signs of major vascular complications. They were 19-63 years). Their mean GFR was 28.2±18.2 ml/1.73 m2 BSA. The renal diagnosis was chronic glomerulonephritis in treated with combinations of long-and short-acting insulin regimens or, in one case, with an insulin pump. One patient nine, chronic interstitial nephritis in five, polycystic kidney disease in two and other or undetermined diagnosis in three was treated for hypertension with a cardioselective betablocking agent.
patients. The mean 24-h urinary protein excretion was 1.2±0.9 g in 17 patients. None of the patients had clinical Twenty patients had renal insufficiency judged to be caused by DN. There were 12 men and eight women with a mean evidence of nephrotic syndrome or other conditions or treatment that would affect lipid metabolism as previously age 43.4 years (range 26-62 years). The mean duration of diabetes was 28.0±5.7 years. All patients had reduced renal described [9]. Total cholesterol ( TC ) and triglyceride ( TG) contents were determined by enzymatic methods as previously described [11] . Concentrations of apolipoproteins A-I, A-II, B, C-II, C-III, and E were measured by electroimmunoassays as previously described [10,12,13]. The isolation of antigens and the preparations of monospecific antisera were described in detail and reported in several publications from this laboratory [10,12,13].
The lipid mass refers to the sum of individually determined (TC ) and ( TG) concentrations and apolipoprotein mass to the sum of individually determined levels of apolipoproteins A-I, A-II, B, C-II, C-III, and E in each of the major lipoprotein density classes.
Statistical methods
Conventional statistical methods were used to describe the salient features of the results. Student's unpaired two-tailed t test was used to test the significance of differences between means. Spearman's rank correlation test was used for the calculation of correlation coefficients.
Results
Plasma TG and TC concentrations were significantly increased in patients with DN, but there was no change in plasma lipids of diabetic patients without nephropathy in comparison with controls ( Table 2) . Diabetic patients with nephropathy had higher TG levels than the non-diabetic CRF patients. Apolipoproteins A-I and A-II were significantly reduced in both diabetic and non-diabetic patients with renal insufficiency with no significant change in the diabetic patients without nephropathy. ApoB concentrations were significantly elevated in patients with DN in comparison with 10.0f
13.5a
14.0b,f controls and diabetic patients without nephropathy. subjects and even higher than that in LDL and HDL of non-diabetic patients with CRF. Patients with DN had significantly higher concentrations of apoC-II than controls or diabetics without
The differences in lipid and apolipoprotein concentrations between patients and controls were clearly nephropathy and non-diabetic CRF patients. Patients with DN had significantly higher levels of apoC-III reflected in the lipid and apolipoprotein masses of their corresponding density classes (Figure 1 ). The most than control subjects or diabetic patients without nephropathy; non-diabetic patients with renal insuffi-affected lipoprotein density classes were VLDL, IDL, and HDL. In comparison with controls, patients with ciency had also higher levels of apoC-II than diabetic patients without nephropathy, but lower concentra-DN were characterized by a more than 4-fold increase in VLDL mass (197.4±123.5 vs 44.8±30.2 mg/dl; tions of apoC-III than patients with DN. In contrast to non-diabetic patients with CRF, both the patients P<0.01), a 3-fold increase in IDL mass (117.1±60.8 vs 34.6±20.7 mg/dl; P<0.001) and a significant reducwith DN and diabetic patients without nephropathy had significantly higher apoE levels than controls.
tion of HDL mass (202.2±51.9 vs 312.6±59.5 mg/dl, P<0.001). Diabetic patients without nephropathy As a consequence of abnormal apolipoprotein levels, the apoA-I/apoC-III and apoA-I/apoB ratios were tended to have low VLDL and LDL masses and no change in the concentration of the HDL mass. significantly reduced, and apoC-III/apoE ratio significantly increased in all patient groups.
In comparison with the non-diabetic patients with CRF, patients with DN had significantly greater VLDL and IDL masses. The proportional increases in apolipoprotein masses in VLDL and IDL and a decrease Lipid and apolipoprotein concentrations in lipoprotein in HDL were considerably greater than those of corresdensity classes ponding lipid masses in patients with DN. Patients with DN had significantly higher concentrations of lipids and apolipoproteins B, C-II, C-III and E in VLDL than controls, diabetics without nephro-Distribution of lipids and apolipoproteins in lipoprotein pathy, and non-diabetic patients with CRF ( Table 3) . density classes These changes were mainly due to increased levels of VLDL lipids and apolipoproteins in diabetic patients Changes in the apolipoprotein masses were closely associated with the distribution of apoB, apoC-III and with elevated triglyceride (>1.7 mmol/l ) levels.
The differences in the levels of lipids and apolipo-apoE between HDL and VLDL, IDL and LDL ( Figure  2 ). The significantly increased concentrations of apoCproteins between patients with nephropathy and controls were also expressed significantly in IDL, III and apoE are paralleled by increased percentage distributions of these apolipoproteins in VLDL and particularly in the non-diabetic patients with CRF ( Table 3) . Significantly higher levels of TC, apoC-IDL; this also applies to apoC-III in LDL but not in HDL. In contrast to patients with DN, patients with peptides, and apoE were observed in all patient populations including increased apoC-II, apoC-III non-diabetic CRF had a smaller percentage redistribution of apoE from HDL to VLDL and IDL and no and apoE concentrations in diabetic patients without nephropathy.
increase in total apoE concentration. However, there was no major qualitative difference in the distribution In LDL, the most characteristic differences between patient groups and controls included significant of apoC-III between diabetic and non-diabetic patients although the former had higher total plasma apoC-III increases in TG, apoC-II and apoC-III. ( Table 3) . Also diabetic patients without nephropathy and non-levels than the latter. There was a 2-fold increase in the percentage distribution of total apoC-III in LDL diabetic patients with CRF showed significant increases of apoC-II and apoC-III in LDL. There was no change of both diabetic and non-diabetic patients with renal insufficiency but no difference in the percentage distriin apoB or apoE concentrations between patient groups and controls. bution of apoE. There were no marked differences in the percentage In HDL, the levels of TC were significantly decreased in patients with DN and non-diabetic patients with distributions of apoB, apoC-III, and apoE in LDL between diabetic and non-diabetic patients with CRF. CRF; the concentrations of TG were insignificantly increased in all patient groups in comparison with The redistribution of apolipoproteins C-III and E is reflected in the reduced percentage distribution of these controls ( Table 3 ). All patients with renal insufficiency had significantly reduced levels of apolipoproteins apolipoproteins in HDL to about 40% of controls (P<0.001). A-I, A-II, C-II and E. The apoB levels were increased in all patient groups reaching statistical significance Patients with DN had significantly increased percentage distributions of TC in VLDL and IDL with in diabetic patients without nephropathy and nondiabetics with CRF.
corresponding decrease in LDL and HDL. Changes in the percentage distribution of total TG, apoA-I and In contrast to non-diabetic patients with CRF, the patients with DN had a lower ratio of apoC-III/apoE apoA-II were insignificant. However, there was a consistent trend towards increased percent distributions of in VLDL than control subjects with no change in IDL. However, the apoC-III/apoE ratio was elevated 5-fold apoA-I and apoA-II in VLDL and IDL of diabetic patients compared to controls. in LDL and 2-fold in HDL in comparison with control 
Composition of lipids and apolipoproteins in lipoprotein
The HDL of diabetic and non-diabetic patients with density classes renal insufficiency were significantly enriched in TG There were no significant differences in lipid or apolipo-in comparison with control subjects (32.3±12.2%, protein composition of VLDL between patients with 27.2±12.9% and 15.4±6.7% respectively, P<0.001 DN and controls or non-diabetic patients with CRF. and <0.05). In contrast to non-diabetic patients with However, in IDL patients with DN had higher relative CRF, the patients with DN had no change in relative contents of any of the HDL apolipoproteins except contents of apoC-II (3.3±1.9 vs 1.5±1.1%; P<0.05) 241.9±44.7 mg/dl; P<0.05) with a marked reduction of HDL-cholesterol (0.82±0.38 vs 1.58±0.45 mmol/l; P<0.001). for a slight increase in the relative apoB content As shown in Table 4 , lipid and apolipoprotein con-(2.7±2.0 vs 0.9±0.3, P<0.05).
centrations in major lipoprotein density classes were influenced by both the extent of proteinuria and the Relationship to renal function, metabolic control and metabolic control of the diabetes reflected in HbA1c proteinuria values. When separated according to GFR values, diabetic patients with more advanced renal failure and GFR Discussion <20 ml/min had significantly higher plasma TG levels (3.1±1.1 vs 1.8±1.4 mmol/l; P<0.05) than patients with GFR >20 ml/min. They also had lower plasma The results of this study show that the concentration, distribution, and composition of lipids and apolipoapoA-I levels (101.9±2.2 vs 127.9±25.7 mg/dl; P<0.05) and a tendency to higher apoC-II (5.7±1.9 proteins in major lipoprotein density classes of patients with insulin-dependent diabetes mellitus and nephrovs 4.0±1.5 mg/dl; P=0.055) and apoC-III levels (26.8±9.6 vs 18.3±7.1 mg/dl; P=0.055). VLDL-pathy differ considerably from those of normal controls and, importantly, insulin-dependent diabetic patients cholesterol levels were higher in patients with GFR <20 ml/min than in patients with GFR >20 ml/min without nephropathy. Further, there are similarities but also differences in these compositional abnormalit-(1.7±0.8 vs 0.7±0.6 mmol/l; P=0.02); this was also the case with IDL-TG (0.57±0.31 vs 0.28± ies between patients with DN and non-diabetic patients with renal disease and comparable renal functional 0.20 mmol/l; P<0.05), IDL-cholesterol (1.29±0.44 Table 4 dyslipoproteinaemia in diabetic patients with CRF [7, 23] . Patients with less efficient control, reflected in higher HbA1c values, had higher levels of TG in impairment [9] . These alterations may result from abnormal lipoprotein metabolism characteristic of plasma and IDL, and, more importantly, apoC-III enriched VLDL, IDL, and LDL. Because there was renal insufficiency and changes related to varying metabolic control of the diabetic condition.
no comparable increase in the levels of apoE, the apoC-III/apoE ratio was significantly increased in all The main underlying disturbance in both diabetic and non-diabetic patients with nephropathy is the these lipoproteins, suggesting increased concentrations of lipoproteins containing apoB and apoC-III. Thus, accumulation of apoB-containing lipoproteins [4]. They are intact or partially depleted of triglycerides the poor metabolic control accentuates lipoprotein abnormalities characteristic of CRF in DN patients but enriched with apoC-peptides and apoE. While more accentuated in hypertriglyceridaemic patients, and, consequently, indicates means to attenuate the dyslipidaemia in these patients. the plasma lipid and apolipoprotein profiles show that these lipoproteins are also present in normotriglyceriAn adequate control of blood pressure reduces proteinuria in patients with DN [24, 25] . Although the daemic patients [9, [14] [15] [16] [17] [18] .
The present study extends our previous observations degree of proteinuria was correlated with increased concentrations of TG and apoC-III in VLDL, IDL of abnormal plasma lipid and apolipoprotein profiles in diabetic patients with nephropathy [7] . Although and LDL, increased IDL mass and decreased HDL mass, the contributory influence in some patients could the apoC-and apoE-enriched apoB-containing lipoproteins mainly accumulate in VLDL and IDL, these not be readily separated from the effect of lower GFR values. lipoproteins are also found in the LDL range. This leads to a marked increase of lipid and apolipoprotein Like in non-diabetic CRF patients, there was a marked relationship between decreasing GFR values masses not only in VLDL but also in IDL. The slightly higher proportion of apolipoproteins to lipids in IDL and increased expression of the renal dyslipidaemia as reflected in higher levels of TG and apoC-III in plasma of both diabetic and non-diabetic patients with renal disease may be related to increased contents of apoC-and among the apoB-containing lipoproteins in VLDL, IDL, and LDL [26 ] . III and apoE. The impaired catabolism of TG-rich lipoproteins may be the major explanation for the Diabetic and non-diabetic patients were selected as a subset for a more detailed analysis of the lipoprotein retention of apoC-peptides and apoE which normally are rapidly transferred to HDL. composition from two larger patient populations as previously described [7] . Although the DN patients The present results also indicate that insulindependent patients without nephropathy and with fair had a slightly lower mean GFR than non-diabetic CRF patients, the range of residual renal function was
We conclude that the lipid transport in diabetic renal insufficiency is characterized by changes in the metabolconsidered to be comparable between the two patient groups. Also patients with DN were characterized by ism of apoB-and apoA-containing lipoproteins that in several respects are similar to those found in nona slightly higher degree of proteinuria in comparison with the non-diabetic CRF patients. This corresponds diabetic patients with comparable degree of renal functional impairment. They may not be reflected in to the clinical setting in which the patients were studied and may be one of the factors that contribute to the elevated plasma lipid concentrations but in distinct changes in the apolipoprotein profile of plasma and specific changes of lipoprotein composition found in DN patients.
major lipoprotein density classes and are modulated by the degree of metabolic control. It appears that the Thus, the expression of the underlying changes in lipoprotein metabolism in insulin-dependent diabetic main underlying abnormality is the retarded catabolism and removal of the apoB-containing lipoproteins patients with nephropathy is modulated both by the degree of renal functional impairment and the meta-and that their structural changes contribute to the catabolic impairment. The compositional changes may bolic control of the diabetic condition. In addition, proteinuria and, although not studied in these patients, enhance their atherogenic potential which remains to be further characterized. nutritional factors and pharmacological treatment may influence the dyslipidemia.
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